contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lidds-will-participate-in-redeyes-fight-cancer-seminar-on-march-10

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

LIDDS is a pharmaceutical company. The company develops pharmaceutical products based on a patented and clinically tested drug delivery technology. The properties of the products form the basis of the LIDDS technology platform for the development of injectable pharmaceutical products. LIDDS is the abbreviation for Local Intelligent Drug Delivery System, and the company is headquartered in Uppsala.

LIDDS

UPPSALA, SWEDEN – LIDDS AB (publ) - LIDDS CEO, Monica Wallter, will present the company at the Redeye Fight Cancer Seminar taking place in Stockholm on March 10, targeting both private and institution...

UPPSALA, SWEDEN – LIDDS AB (publ) - LIDDS CEO, Monica Wallter, will present the company at the Redeye Fight Cancer Seminar taking place in Stockholm on March 10, targeting both private and institutional investors and media. Monica will also take part in a panel debate together with other presenting companies at the seminar. The seminar gathers ten companies involved in developing different new treatment opportunities for fighting cancer. Monica will be presenting LIDDS at 11.40 AM and take part in the panel discussion at 11.50 AM.The seminar can be followed live at: <a href="https://www.globenewswire.com/Tracker?data=qOgOJ48Hem8ExLvuadzwa5F5xWHI3oeOa_2W4JJ8mFKQgF__l5j3sKMryHur-4PCWm3vGtiUALNkl5u00sSuN6YyFqhz_6a1cgyLTfCbYNmnwWY4IU4nG1DYYK4fXue2IX_NVAYXqOC3qMcZ4jkkRYdoekObVPXHWlI4hNIvoKg=">https://www.redeye.se/live/fight-cancer-10-mar</a>For more information, please contact:Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: <a href="https://www.globenewswire.com/Tracker?data=PALA6jtGYyluj6U2qiveSAwIP8dh5i2zpAa93psWMdEItDK_vNuw8ic3OYDr5d4SHmWHy0q09ra8tqvPBf2uMNTfMloKYBq7MuI3J1SmQ3C7GD0wvsHxYhvo1jyQqsiD">monica.wallter@liddspharma.com</a>LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, <a href="https://www.globenewswire.com/Tracker?data=uKh6QxFWhjJ8OHAX_XouVbdIyvQjSuhdIQUpg0ATcI-LVD9Tz2C1E8GoAj-bTUrgxeTToobmnT7hKIhe7DT57Qa2X1wMw6IQ7fJQuwzZ2Lw6jyF8zZejVCwYTITZT1Iu">certifiedadviser@redeye.se</a>, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com. Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/2fab5ea6-5547-4acc-a459-d20c93b3dc61">LIDDS News 200305 Redeye seminar</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMDMyMjE0NCM0MDA2MDkyNTAjMjAwMzY2Mg==" width="1" height="1"/>

LIDDS will participate in Redeye’s Fight Cancer Seminar on March 10

Talouden myyttejä murtamassa: Saksan teollisuus on menneen talven lumia

Federal Reserven korkopäätös: Riidankylväjät vauhdissa

On pakko painaa pitkää päivää? Ekonomisti fundeeraa

Nousuviikko takana, USA:n työllisyystaantuma ei edelleenkään luvuissa

Taloustieteen myyttejä murtamassa: Datakeskusinvestoinnit johtavat aina vain parempaan tekoälyyn